Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 28, 2023

Pyrotinib vs Placebo Plus Trastuzumab and Docetaxel as a First-Line Treatment for HER2-Positive Metastatic Breast Cancer

BMJ: British Medical Journal


Additional Info

BMJ: British Medical Journal
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
BMJ 2023 Oct 31;383(xx)e076065, F Ma, M Yan, W Li, Q Ouyang, Z Tong, Y Teng, Y Wang, S Wang, C Geng, T Luo, J Zhong, Q Zhang, Q Liu, X Zeng, T Sun, Q Mo, H Liu, Y Cheng, J Cheng, X Wang, J Nie, J Yang, X Wu, X Wang, H Li, C Ye, F Dong, S Wu, X Zhu, B Xu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading